Using three different cohorts, they demonstrated that levels of glutamate receptor 2 (GluR2) and proBDNF, but not mature BDNF, in GAP43+/NLGN3+ EVs are lower in early AD compared to controls. This evidence concerns the gene GAP43 and Alzheimer disease.